List of Tables
Pfizer Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 22
Pfizer Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 23
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 24
Pfizer Inc, Deals By Therapy Area, 2011 to YTD 2017 25
Pfizer Inc, Medical Devices Deals, 2011 to YTD 2017 27
Pfizer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 28
Pfizer to Acquire Neksium Brand from AstraZeneca 52
Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 53
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 55
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 56
Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 58
Bamboo Therapeutics Acquires Viral Gene Therapy Manufacturing Facility from University of North Carolina 60
Medivation Acquires Rights to Talazoparib from BioMarin Pharma 61
Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 62
Bamboo Therapeutics Acquires Rights to Canavan Disease Proposed Drug from Rowan University 63
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 64
Pfizer Acquires Portfolio of Vaccines from Baxter for USD648 Million 65
Hospira Healthcare Completes Acquisition of Manufacturing and R&D Facility from Orchid Chemicals & Pharma for USD218 Million 67
Pfizer Acquires Melanocortin Receptors from MRC Technology 69
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 70
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 71
Pfizer Completes Acquisition Of Polocard From Polpharma For US$32 Million 72
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 73
Esperion Therapeutics Acquires 4WF from Cleveland Clinic 74
Pfizer Exercises Option To Acquire Manufacturing Facility In Rouses Point From Akrimax 75
Pfizer Acquires Product Portfolio from Akorn-Strides 76
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 77
Cydan Raises USD34 Million in Venture Financing 79
Palleon Pharma Raises USD47.6 Million in Series A Financing 80
SpringWorks Therapeutics Raises USD103 Million in Series A Financing 81
Complexa Raises USD62 Million in Series C Financing 83
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 84
Neuronetics Raises USD15 Million in Series G Round of Financing 86
Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 88
Rhythm Pharma Raises USD41 Million in Mezzanine Financing 90
Circle Pharma Raises Funds through Series A Preferred Stock Financing 92
Ixchelsis Raises Additional USD12 Million in Venture Financing 93
Vtesse Raises USD17 Million in Extended Series A Financing 94
Second Genome Raises USD8.4 Million in Extended Series B Financing 95
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 96
Storm Therapeutics Raises USD16 Million in Series A Venture Financing 97
Blade Therapeutics Raises USD27 Million in Series B Financing 98
Second Genome Raises USD42.6 Million in Series B Financing 100
Cydan Development Raises USD31 Million in Series A Financing 102
Metabomed Raises USD18 Million in Series A Venture Financing 103
Mission Therapeutics Raises USD85.7 Million in Financing Round 104
Biodesy Raises USD10 Million in Series B Financing 106
Lodo Therapeutics Raises USD17 Million in Series A Financing 107
Bamboo Therapeutics Raises USD49.5 Million in Venture Financing 109
NextCure Raises USD67 Million in Series A Financing 110
Petra Pharma Raises USD48 Million in Series A Financing 112
Cortexyme Raises USD15 Million in Series A Financing Round 114
Merus Raises USD46.4 Million in First Tranche of Series C Financing 115
Rhythm Metabolic Raises USD40 Million in Series A Financing Round 117
Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 119
Mirna Therapeutics Raises USD41.8 Million in Series D Financing 120
Nimbus Therapeutics Raises USD43 Million in Series B Financing 122
Mersana Therapeutics Raises USD35 Million in Series B Financing 123
Vtesse Raises USD25 Million in Series A Financing 124
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 125
Ziarco Raises USD33 Million in Series B Venture Financing 126
Quartet Medicine Raises USD17 Million in Series A Venture Financing 127
Circle Pharma Raises Funds through Seed Financing 128
Epic Sciences Raises USD30 Million in Series C Venture Financing 129
NexImmune Raises USD3 Million in Venture Financing 130
Mission Therapeutics Raises US$32 Million In Series B Financing 131
Biodesy Raises US$15 Million In Series A Financing 132
Merus Raises US$42 Million In Extended Series B Financing 133
Cydan Raises US$26 Million In Venture Financing 135
Esperion Therapeutics Raises US$33 Million In Venture Financing 137
Aquinox Pharma Raises US$18 Million In Series C Financing 139
Esperion Therapeutics Raises US$1 Million In Venture Financing 140
Flexion Therapeutics Raises US$20 Million In Series B Financing 141
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 142
Rhythm Pharma Raises US$33 Million In Series B Financing 143
Epic Sciences Raises US$13 Million In Series B Financing 145
Ziarco Pharma Raises US$6 Million In First Tranche Of Series A financing 146
Mirna Therapeutics Raises US$34 Million In Series C Financing 147
Mersana Therapeutics Raises US$27 Million In Series A-1 Financing 149
InnoPharma Raises US$8 Million In Venture Financing 151
Flexion Therapeutics Raises Additional US$13 Million In Series A Financing 152
Celladon Raises Additional US$10 Million In Series D Financing 153
InnoPharma Secures US$15 Million In Series A Financing Round 155
Neuronetics Secures US$30 Million In Series E Financing 156
NextWave Pharma Secures US$45 Million In Series C Financing Round 158
TetraLogic Pharma Secures US$23 Million In Second Tranche Of Series C Financing 160
Bain Capital May Acquire Laboratorio Teuto Brasileiro 162
Kohlberg Kravis Completes Acquisition Of Capsugel From Pfizer 163
Pfizer Enters into Licensing Agreement with Scripps Research Institute 165
Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 166
University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 167
Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 168
Alcyone Lifesciences Enters into Agreement with Pfizer 169
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 170
Astellas Pharma Amends Agreement with Pfizer 171
EpiThany Enters into Agreement with Merck and Pfizer 172
VAXIMM Enters into Agreement with Merck and Pfizer 173
Domain Therapeutics Enters into Partnership with Pfizer 174
Pfizer Enters into Agreement with Washington University in St. Louis 175
Edelris Enters into Research Agreement with Pfizer 176
AbCellera Biologics Enters into Research Agreement with Pfizer 177
Pfizer Partners with NovaMedica 178
PegBio Partners with Pfizer 179
Pfizer Enters into Agreement with National Cancer Institute 180
Debiopharm Partners with Merck and Pfizer 181
Transgene Enters into Agreement with Merck and Pfizer 182
Circle Pharma Partners with Pfizer 183
Pfizer and CR Saike Pharma Enter into Distribution Agreement 184
Pfizer Partners with inVentiv Health 185
Fuji Yakuhin and Pfizer Enter into Co-Promotion Agreement 186
BioRap Technologies Enters into Co- Development Agreement with Pfizer 187
Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 188
Merck, Pfizer and Verastem Enter into Agreement 189
Pfizer Enters into Agreement with California Institute for Biomedical Research 190
Pfizer Enters into Research Agreement with Adaptive Biotech 191
Merck, Pfizer and Syndax Pharma Enter into Agreement 192
Heptares Therapeutics Enters into Agreement with Pfizer 193
Pfizer Enters into Agreement with Biovac Institute 194
Pfizer Enters into Agreement with GlaxoSmithKline 195
Mayne Pharma Enters into Distribution Agreement with IDT Australia 196
Pfizer Enters into Agreement with Synthon 197
Centers for Therapeutic Innovation Enters into Research Agreement with Jeffrey Modell Foundation 198
CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 199
Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 200
Regimmune Enters into Research Agreement with JDRF and Pfizer 201
BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 202
HiFiBiO Enters into Research Agreement with Pfizer 203
Alzheimer Drug Discovery Enters into Research Agreement with CTI for Alzheimer's Disease Drugs 204
University of Dundee Enters into Research Agreement with Pfizer 205
HemoShear Enters into Agreement with Pfizer 206
Pfizer Enters into Co-Development Agreement with Merck 207
Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 209
Crohn’s & Colitis Foundation of America and Pfizer Enter into Agreement for Inflammatory Bowel Disease 210
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 211
Pfizer Enters into Development Agreement with Cellectis 213
X-Chem Enters into Co-Development Agreement with Pfizer 214
KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 215
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 216
BioRestorative Therapies Enters into Research Agreement with Pfizer 217
Process Systems Enters Into Co-Development Agreement With Pfizer 218
Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 219
Octapharma Enters Into Co-Marketing Agreement With Pfizer 220
Protagen Enters Into Biomarker Discovery Agreement With Pfizer 221
Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 222
Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 223
Sanford-Burnham Medical Research Institute Enters Into Research Agreement With Pfizer 224
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 225
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 227
Karo Bio Extends Research Agreement With Pfizer For RORgamma Modulators 229
Pfizer Plans To Form Joint Ventures To Accelerate Drug Development 230
Cytomx Therapeutics Enters Into Co-Development Agreement With Pfizer For Oncology Drug Conjugates 231
Centers For Therapeutic Innovation Partners with UC San Francisco 233
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 234
Anacor Pharma Ammends its Research Agreement With Bill & Melinda Gates Foundation 235
Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 236
KineMed Extends Research Agreement With Pfizer 237
OxOnc Development Enters Into Co-Development Agreement With Pfizer For Crizotinib 238
AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 240
Cystic Fibrosis Foundation Therapeutics Enters Into Research Agreement With Pfizer For Cystic Fibrosis Drugs 241
Apredica Enters Into Research Agreement With Pfizer 242
Mochida Pharma Enters Into Agreement With Hospira Japan To Distribute And Promote Oncology Products 243
Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 244
Visterra Enters Into Agreement With Pfizer To Discover Novel Antibodies 245
SFJ Pharma Enters Into Co-Development Agreement With Pfizer For Dacomitinib 246
Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 247
Nodality Enters Into Agreement With Pfizer For Single Cell Network Profiling Technology 248
Pfizer Enters Into Co-Development Agreement With Harvard University 249
Cold Spring Harbor Labs Enters Into Research Agreement With Pfizer For New Cancer Therapies 250
Ildong Pharma Enters Into Co-Promotion Agreement With Pfizer Pharma For Generic Drugs 251
Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 252
Pfizer Enters into Co-Promotion Agreement with Specpharm 253
Pfizer Plans To Enter Into Co-Development Agreement With India-Based Pharma Company 254
Pfizer Enters Into Co-Marketing Agreement With Biologics For Inlyta 255
ICM Enters into Research Collaboration with Pfizer 256
KineMed Enters Into Co-Development Agreement With Pfizer 257
SFJ Pharma Enters Into Co-Development Agreement With Pfizer 258
CollPlant Enters Into Research Agreement With Pfizer For Orthopedic Product 259
Karo Bio Enters Into Research Agreement With Pfizer For RORgamma Modulators 260
Children's Hospital Boston Enters Into Research Agreement With Pfizer 262
Sanford-Burnham Medical Research Institute Enters Into Agreement With Pfizer 263
Pfizer Enters Into Research Agreement With Medco Health Solutions And United BioSource 264
deCODE genetics Enters Into Research Agreement With Pfizer 266
Exonhit Enters Into Research Agreement With Pfizer 267
Anacor Pharma Amends And Expands Research Collaboration With GlaxoSmithKline 268
Anacor Pharma And Medicines For Malaria Venture Extend Co-Development Agreement For AN3661 270
Pfizer Announces Co-Development Agreement With University Of California, San Diego 271
Pfizer Amends Its Co-Promotion Agreement With Astellas Pharma 273
The University Of Queensland Enters Into Co-Development Agreement With Pfizer Australia 274
BioPontis Alliance Enters Into Co-Development Agreement With Pfizer 275
Pfizer Signs MOU To Form Joint Venture With Shanghai Pharma 276
Zacharon Pharma Enters Into Research Collaboration With Pfizer 277
Pfizer Enters Into Co-Promotion Agreement With Daiichi Sankyo For Benicar 278
Selventa Enters Into An Agreement With Pfizer 279
iOWH Enters Into Research Agreement With Anacor Pharma 280
Charles River Labs Enters Into Distribution Agreement With Pfizer 281
Philochem Enters into Discovery Agreement with Pfizer 282
Anacor Pharma Enters Into Research And Development Agreement With Medicis Pharma 283
Pfizer Japan Enters Into Co-Promotion Agreement With Takeda Pharma 284
Pfizer Japan Extends Co-Promotion Agreement With Takeda Pharma 285
MdxHealth Enters Into Co-Development Agreement With Newcastle University, Cancer Research Technology And Pfizer 286
Theraclone Sciences Enters Into Co-Development Agreement With Pfizer 288
Sutro Biopharma Enters Into Collaboration With Pfizer 289
Santaris Pharma Expands Its Collaboration With Pfizer 290
SpringWorks Therapeutics Receives Rights from Pfizer 291
Pfizer Amends Licensing Agreement with Basilea Pharma 292
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 293
Pfizer Enters into Licensing Agreement with HitGen 294
Absorption Systems Enters into Licensing Agreement with Pfizer 295
Pfizer Enters into Licensing Agreement with BioInvent International 296
Pfizer Enters into Licensing Agreement with Ab Initio Biotherapeutics 297
Pfizer Enters into Licensing Agreement with OncoImmune 298
Shire Enters into Licensing Agreement with Pfizer 299
Pfizer Enters into Licensing Agreement with WAVE Life Sciences 300
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 301
Pfizer Enters into Licensing Agreement with 4D Molecular Therapeutics 303
Pfizer Exercises Option for Licensing Agreement with Bind Therapeutics 304
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 305
Pfizer Amends Licensing Agreement with Spark Therapeutics 306
MedGenesis Therapeutix Enters into Licensing Agreement with Pfizer 308
Tabuk Pharma Enters into Licensing Agreement with Pfizer 309
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 310
AstraZeneca Enters Into Licensing Agreement With Pfizer For Nexium 311
Verastem Enters into Licensing Agreement with Pfizer 313
GlycoMimetics Enters Into Licensing Agreement With Pfizer For GMI-1070 314
MedImmune To Enter Into Licensing Agreement With Pfizer 316
Puma Biotech Amends License Agreement with Pfizer for Neratinib 317
Clovis Oncology Amends Licensing Agreement with Pfizer for PF-01367338 319
Gemphire Therapeutics Enters into Licensing Agreement with Pfizer 321
Pfizer Enters into Option Agreement with AnTolRx 322
Pfizer Enters into Licensing Agreement with Western Oncolytics 323
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 324
Iterum Therapeutics Enters into Licensing Agreement with Pfizer 325
Pfizer Enters into Licensing Agreement with KineMed 326
Pfizer Enters into Licensing Agreement with BioAtla 327
Pfizer Enters into Licensing Agreement Servier for UCART19 328
Pfizer Enters into Licensing Agreement with Evotec 329
Tris Pharma Enters into Licensing Agreement with Pfizer Consumer Healthcare 330
Clinigen Extends Licensing Agreement with Hospira for Foscavir 331
Genedata Enters into Licensing Agreement with Pfizer 332
Opko Health Enters into Licensing Agreement with Pfizer 333
Philogen Exercises Option for Licensing Agreement with Pfizer 335
Medivation Exercises Option for Licensing Agreement with CureTech for Pidilizumab 336
iTeos Therapeutics Enters into Licensing Agreement with Pfizer 338
Absorption Systems Enters into Licensing Agreement with Pfizer 339
Kissei Pharma Enters Into Licensing Agreement With Pfizer For KUX-1151 340
Champions Oncology Enters into Licensing Agreement with Pfizer 341
Orion And Hospira Extend Licensing Agreement For Precedex 342
IRICoR And University Of Montreal Enter Into Licensing Agreement With Pfizer 343
Gliknik Enters Into Licensing Agreement With Pfizer For GL-2045 345
Biowa And Lonza Enters Into Licensing Agreement With Pfizer For Potelligent CHOK1SV 347
Harbour Antibodies Enters Into Licensing Agreement With Pfizer For Human Monoclonal Antibodies 348
Sequella Enters Into Licensing Agreement With Pfizer For Sutezolid 349
Bioventus Enters Into Licensing Agreement With Pfizer For Bone Morphogenetic Protein Portfolio 350
Abcam Enters Into Licensing Agreement With Pfizer 351
Hospira Enters into Licensing Agreement with NovaQuest for Erythropoietin Biosimilar 352
Hospira Enters into Licensing Agreement with NovaQuest for Pegylated Filgrastim 354
Hospira Enters into Licensing Agreement with NovaQuest for Filgrastim 355
Tetragenetics Enters Into Option For Licensing Agreement With Pfizer For SionX Technology 356
Philogen Enters Into Licensing Agreement With Pfizer For Dekavil 357
Pfizer Enters Into Licensing Agreement With Halozyme Therapeutics To Develop Biologics 358
NobelPharma Enters Into Licensing Agreement With Pfizer For Sirolimus 360
Ziarco Pharma Enters Into Licensing Agreement With Pfizer 361
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 362
VLST Enters Into Licensing Agreement With Pfizer For Anti-CD40 Monoclonal Antibody 363
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 364
Pfizer Enters Into Licensing Agreement With Biocad For Hemophilia Drug 366
Pfizer Enters Into Licensing Agreement With SatRx For PF-00734200 367
Quark Pharma Amends Licensing Agreement With Pfizer For PF-655 368
FAES Farma And Pfizer Expand Bilastine License Agreement To 21 New Markets In Latin America 370
Lumena Pharma Enters Into Licensing Agreement With Pfizer For LUM001 371
Ligand Pharma Enters Into Licensing Agreement With Hospira 372
Antares Pharma Enters Into Licensing Agreement With Pfizer Consumer Healthcare 373
Sanofi Enters Into Licensing Agreement With Pfizer 374
Jennewein Biotechnologie Enters Into Licensing Agreement With Pfizer 375
Clinigen Enters Into Licensing Agreement With Hospira For Foscavir 376
Abbott Labs Enters Into Licensing Agreement With Pfizer 377
Cell Signaling Technology Enters Into Licensing Agreement With Pfizer 378
Oxford BioMedica Amends Licensing Agreement With Pfizer 379
Seattle Genetics Enters Into Licensing Agreement With Pfizer 380
Kiadis Pharma Enters Into Licensing Agreement With Hospira For ATIR 381
Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 382
Mayne Pharma Raises USD257 Million in Rights Offering of Shares 384
Aquinnah Pharma Raises USD10 Million in Private Placement of Shares 386
Western Oncolytics Raises Funds in Private Placement of Shares 387
AnTolRx to Raise USD4 Million in Private Placement of Shares 388
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 389
Sosei Group Raises USD33 Million in Private Placement of Shares 391
Protalix BioTherapeutics Raises USD10 Million in Private Placement of Shares 392
HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 393
Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 394
Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 396
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 398
Anacor Pharma Files Registration Statement For Public Offering Of Securities For Up To US$50 Million 399
Esperion Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$70 Million 400
Anacor Pharma Completes Public Offering Of Common Stock For US$23 Million 402
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 403
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 404
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 405
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 407
Anacor Pharma Completes Public Offering Of Common Stock For US$24 Million 408
Anacor Pharma Completes Public Offering Of Common Stock For US$21.5 Million 409
Pfizer Raises USD1.06 Billion in Private Placement of 4.2% Notes Due 2047 411
Pfizer Raises USD1.3 Billion in Public Offering of Notes Due 2019 413
Pfizer Raises USD793.5 Million in Public Offering of 1% Notes Due 2027 415
Pfizer Raises USD1.06 Billion in Public Offering of Notes Due 2020 417
Pfizer Raises USD1.06 Billion in Public Offering of 0.25% Notes Due 2022 419
Pfizer Raises USD1.3 Billion in Public Offering of 4.125% Notes Due 2046 421
Pfizer Raises USD1 Billion in Public Offering of 1.7% Notes Due 2019 423
Pfizer Raises USD1 Billion in Public Offering of 4% Notes Due 2036 425
Pfizer Raises USD1 Billion in Public Offering of 2.2% Notes Due 2021 427
Pfizer Raises USD1.8 Billion in Public Offering of 3% Notes Due 2026 429
Pfizer Raises USD0.85 Billion in Public Offering of 1.45% Notes Due 2019 431
Pfizer Raises USD1.25 Billion in Public Offering of 2.75% Notes Due 2026 433
Pfizer Raises USD1.25 Billion in Public Offering of 1.2% Notes Due 2018 435
Pfizer Raises USD0.5 Billion in Public Offering of 4.4% Notes Due 2044 437
Pfizer Raises USD1.15 Billion in Public Offering of 1.95% Notes Due 2021 439
Anacor Pharma Raises USD287.5 Million in Private Placement of 2% Notes Due 2023 441
Anacor Pharma Raises USD82.5 Million Private Placement of Notes Due 2021 443
Anacor Pharma Raises USD8 Million in Private Placement of Notes Due 2021 445
Pfizer Completes Public Offering Of Notes Due 2044 For USD500 Million 447
Pfizer Completes Public Offering Of Notes Due 2017 For USD1 Billion 449
Pfizer Completes Public Offering Of Floating Rate Notes Due 2017 For USD500 Million 451
Pfizer Completes Public Offering Of Due 2024 For USD1 Billion 453
Pfizer Completes Public Offering Of Notes Due 2019 For USD1.5 Billion 455
Pfizer Completes Public Offering Of Notes Due 2018 For US$1 Billion 457
Pfizer Completes Public Offering Of Notes Due 2017 For US$750 Million 459
Pfizer Completes Public Offering Of Notes Due 2018 For US$500 Million 461
Pfizer Completes Public Offering Of Notes Due 2023 For US$1 Billion 463
Pfizer Completes Public Offering Of Notes Due 2043 For US$750 Million 465
Medivation Completes Public Offering Of 2.625% Convertible Senior Notes Due 2017 For US$259 Million 467
Pfizer May Sell Consumer Healthcare Business 469
CordenPharma to Acquire API Manufacturing Facility from Pfizer 470
Avara Pharma to Acquire Sterile Manufacturing from Pfizer 471
ICU Medical Acquires Hospira Infusion Systems Business from Pfizer 472
Pfizer May Sell its Portfolio of Drugs 474
Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 475
Sandoz Acquires Rights of Biosimilar Infliximab from Pfizer 476
Vidhi Research to Acquire Thane Plant from Pfizer for USD27 Million 477
Alvogen to Acquire Four Pharma Products from Pfizer 478
XRpro Sciences Acquires Certain Assets of Icagen from Pfizer 479
R-Pharm Acquires Production Plant in Illertissen, Germany from Pfizer 481
Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 483
UPM Pharma To Acquire Manufacturing Facility In Bristol From Pfizer 484
Neolpharma Completes Acquisition Of Manufacturing Plant In Puerto Rico From Pfizer 485
Labrys Biologics Acquires RN-307 from Pfizer 486
Nuron Biotech Acquires Meningitis C Vaccine, Meningitec From Pfizer 487
Sinoxa Pharma Acquires Patent Rights To 5-HT2A+2B Antagonists From Pfizer 488
Fareva Acquires Henrico County Manufacturing Plant from Pfizer 489
Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 490
BioMarin Completes Acquisition Of Biologics Manufacturing Plant In Ireland From Pfizer For US$50 Million 492
Amgen Completes Acquisition Of Dublin Sterile Plant From Pfizer 493
Pfizer Plans The Sale Of Its Four Divisions 495
Nuron Biotech Acquires Assets Related To HibTITER From Wyeth 496
Sapphire I (HK) Holdings Acquires 49% stake in Hisun-Pfizer Pharma 497
Paratek Pharma May Sell Itself 498
Pfizer May Sell 40% Stake in Laboratorio Teuto Brasileiro 500
Pfizer Acquires 50% Stake in IGNITE Immunotherapy 501
Pfizer Acquires Medivation in Tender Offer 502
Pfizer Acquires Bamboo Therapeutics 504
Teva Pharma, Mylan May Acquire Teut|Pfizer 505
Pfizer Acquires Anacor Pharma for USD5.2 Billion 507
Pfizer Acquires Treerly Health from Sirio Pharma 509
Pfizer Acquires Hospira for USD17 Billion 510
Pfizer May Acquire Remaining 90.5% Stake in Cellectis 512
Pfizer Acquires Minority Stake in AM-Pharma 513
Pfizer May Increase Bid to Acquire AstraZeneca 514
Pfizer Acquires Controlling Interest in Redvax 516
Pfizer Acquires InnoPharma for USD360 Million 517
Pfizer May Acquire Actavis 518
Pfizer May Acquire Bristol-Myers Squibb 519
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 520
Biocad Rumored To Sell Itself For Up To US$1 Billion 521
Pfizer, Novartis And Abbott Labs Reportedly Plan To Bid For Ache Labs 522
Pfizer Rumored To Acquire Rexahn Pharma 524
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 525
Nestle Completes Acquisition Of Pfizer Nutrition From Pfizer For US$11.85 Billion 527
Pfizer Completes Acquisition Of NextWave Pharma, Attention-Deficit Drug Maker, For Up To US$700 Million 529
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 531
Pfizer Acquires Alacer, Vitamin Supplements Company 533
Pfizer Completes Acquisition Of Skin Scarring Drugmaker Excaliard Pharma 534
Pfizer Completes Acquisition Of Ferrosan Consumer Health 536
Pfizer Completes Acquisition Of Icagen For US$49.8 Million 538
Pfizer Acquires King Pharma 540
Pfizer Inc, Key Competitors 542
Pfizer Inc, Key Employees 543
Pfizer Inc, Subsidiaries 545
Pfizer Inc, Joint Venture 568